In vivo activity of vancomycin combined with colistin against multidrug-resistant trains of Acinetobacter baumannii in a Galleria mellonella model

Infectious Diseases

Volumn 48, Issue 3, 2016, Pages 189-194

  Yang, Haifei ^a   Lv, Na ^a   Hu, Lifen ^a   Liu, Yanyan ^a,b   Cheng, Jun ^a   Ye, Ying ^a,b   Li, Jiabin ^a,b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Anhui Center for Surveillance of Bacterial Resistance   (China)

Author keywords

Acinetobacter baumannii; Colistin; Galleria mellonella; Insect model; Vancomycin

Indexed keywords

COLISTIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHROPOD LARVA; ARTICLE; BACTERIAL GROWTH; BACTERIAL REGROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; GALLERIA MELLONELLA; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; SURVIVAL RATE; ACINETOBACTER INFECTIONS; ANIMAL; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG EFFECTS; HUMAN; LARVA; MOTH;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; COLISTIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; LARVA; MOTHS; VANCOMYCIN;

EID: 84962234060     PISSN: 23744235     EISSN: None     Source Type: Journal    
DOI: 10.3109/23744235.2015.1103894     Document Type: Article

References (26)

1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008; 21:538-582.
2. Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter bau-mannii: mechanisms of virulence and resistance. Int J Antimicrob Agents. 2010;35:219-226.
3. Hornsey M, Ellington MJ, Doumith M, et al. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Antimicrob Chemother. 2010;65:1589-1593.
4. Park YK, Jung SI, Park KH, et al. Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea. Diagn Microbiol Infect Dis. 2009;64:43-51.
5. Ko KS, Suh JY, Kwon KT, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother. 2007;60:1163-1167.
6. Rodriguez CH, Bombicino K, Granados G, et al. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis. 2009;65:188-191.
7. Tan TY, Ng LS, Tan E, Huang G. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter bauman-nii clinical isolates. J Antimicrob Chemother. 2007;60:421-423.
8. Tripodi MF, Durante-Mangoni E, Fortunato R, et al. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapene-mases. Int J Antimicrob Agents. 2007;30:537-540.
9. Wareham DW, Bean DC. In vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann Clin Microbiol Antimicrob. 2006;5:10. doi:10.1186/1476-0711-5-10.
10. Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54:5316-5322.
11. Hornsey M, Wareham DW. In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2011;55:3534-3537.
12. Champion OL, Cooper IA, James SL, et al. Galleria mellonella as an alternative infection model for Yersinia pseudotuberculosis. Microbiology. 2009;155:1516-1522.
13. Jander G, Rahme LG, Ausubel FM. Positive correlation between virulence of Pseudomonas aeruginosa mutants in mice and insects. J Bacteriol. 2000;182:3843-3845.
14. Kavanagh K, Reeves EP. Exploiting the potential of insects for in vivo pathogenicity testing of microbial pathogens. FEMS Microbiol Rev. 2004;28:101-112.
15. Bryson V, Szybalski W. Microbial selection. Science. 1952;116:45-51.
16. Woodford N, Ellington MJ, Coelho JM, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2006;27:351-353.
17. CLSI. Performance standards for antimicrobial susceptibility testing; Twenty-Fourth informational supplement, M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
18. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-281.
19. Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections, a prospective, open-label, uncontrolled study. Clin Ther. 2008;30:143-151.
20. Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother. 2009;53:1863-1867.
21. Peleg AY, Jara S, Monga D, et al. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother. 2009;53:2605-2609.
22. Sarkar S, DeSantis ER, Kuper J. Resurgence of colistin use. Am J Health Syst Pharm. 2007;64:2462-2466.
23. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29:1275-1279.
24. Vidaillac C, Benichou L, Duval RE. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2012;56:4856-4861.
25. Bergen PJ, Tsuji BT, Bulitta JB, et al. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmaco-dynamic model. Antimicrob Agents Chemother. 2011;55:5685-5695.
26. O'Hara JA, Ambe LA, Casella LG, et al. Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter bauman-nii clinical strains. Antimicrob Agents Chemother. 2013;5:2103-2108.